Browsing by Subject "aminotransferase blood level"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Increased transaminase levels coexistent with pseudo-obstruction; [Çölyak hastaliǧinda transaminaz yüksekliǧi ile psödo-obstrüksiyonun birlikteliǧi](2003) Polat M.; Kasirga E.; Ersoy B.; Abay I.; Onaǧ A.Celiac disease is an intestinal reaction towards gluten which causes a defect in the digestive system. Although celiac disease presents with typical malabsorption symptoms, it can also cause atypical gastrointestinal system symptoms (discomfort). Among case reports in the literature related with atypical celiac disease, there has been no celiac disease case who presented with pseudo-obstruction and increased liver enzymes. In this paper, we report a nine-year-old celiac patient who presented with pseudo-obstruction symptoms and increased aminotransferase level.Item Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome(Elsevier Masson SAS, 2004) Güçlü F.; Özmen B.; Hekimsoy Z.; Kirmaz C.Background. - In West of Scotland Coronary Prevention Study (WOSCOPS), development of type 2 diabetes mellitus (DM) was found to decrease by 30% in pravastatin-treated patients. In the study, it is suggested that pleiotropic effects of pravastatin may be responsible too as well as its lipid lowering effect. Objective. - The aim of this study was to assess the effects of pravastatin treatment on the insulin resistance in patients with metabolic syndrome with impaired glucose tolerance (IGT), by Homeostasis Model Assessment (HOMA) test, insulin sensitivity indices and glucose half activation time (glucose t1/2). Methods. - Study population consisted of 25 women who were diagnosed with metabolic syndrome. At baseline and 10 weeks after the 20 mg/daily tablet pravastatin treatment, waist/hip circumference, body weight and arterial blood pressure measurements, plasma glucose, total cholesterol, triglyceride, high density lipoprotein (HDL)-cholesterol, transaminases, glycosylated haemoglobin (A1C) and insulin level measurements were obtained along with HOMA test and insulin tolerance test after 12 h of fasting. Insulin sensitivity indices and glucose t1/2 were assessed. Results. - After the treatment, a statistically significant decrease was observed in arterial blood pressure values (P < 0.0001). While plasma total cholesterol, low density lipoprotein (LDL)-cholesterol, and triglyceride levels were found to decrease significantly and HDL-cholesterol levels increased significantly, a decrease in baseline insulin levels, an increase in insulin sensitivity levels were observed along with an decrease in glucose t1/2. Related to the improvement in aforementioned parameters, statistically significant decreases were noted in HOMA, postprandial and fasting glucose levels and A1C values (P < 0.0001). Conclusion. - Our study suggests that using pravastatin in the dyslipidemia treatment of metabolic syndrome with IGT may be an effective approach by its advantageous effects on insulin resistance. Based on this result, it is possible to say that this can be a risk lowering treatment approach for the development of type 2 DM. © 2004 Elsevier SAS. All rights reserved.Item Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients(Springer Nature, 2024) Erduran F.; Emre S.; Hayran Y.; Adışen E.; Polat A.K.; Üstüner P.; Öztürkcan S.; Öztürk P.; Ermertcan A.T.; Selçuk L.B.; Aksu E.K.; Akbaş A.; Kalkan G.; Demirseren D.; Kartal S.P.; Topkarcı Z.; Kılıç A.; Yaldız M.; Aytekin S.; Hızlı P.; Gharehdaghi S.; Borlu M.; Işık L.; Botsalı B.R.; Solak E.Ö.; Albayrak H.; Gönülal M.; Balcı D.D.; Polat M.; Daye M.; Ataseven A.; Yıldız S.; Özer İ.; Zorlu Ö.; Doğan S.; Erdemir V.A.; Dikicier B.S.Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (IQR = 5–15). The median weekly dose was 15 mg (IQR = 11–15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (P = 0.011), subcutaneous administration (P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (P = 0.001), baseline PASI ≥ 10 (P < 0.001), no prior systemic treatment (P < 0.004), folic acid use (P = 0.001) and absence of comorbidities (P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.